0001127602-23-010081.txt : 20230314 0001127602-23-010081.hdr.sgml : 20230314 20230314161824 ACCESSION NUMBER: 0001127602-23-010081 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230313 FILED AS OF DATE: 20230314 DATE AS OF CHANGE: 20230314 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Alpuche Charles CENTRAL INDEX KEY: 0001665678 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33462 FILM NUMBER: 23731245 MAIL ADDRESS: STREET 1: C/O INSULET CORPORATION STREET 2: 600 TECHNOLOGY PARK DRIVE, SUITE 200 CITY: BILLERICA STATE: MA ZIP: 01821 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INSULET CORP CENTRAL INDEX KEY: 0001145197 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 043523891 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 NAGOG PARK CITY: ACTON STATE: MA ZIP: 01720 BUSINESS PHONE: 978-600-7000 MAIL ADDRESS: STREET 1: 100 NAGOG PARK CITY: ACTON STATE: MA ZIP: 01720 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2023-03-13 0001145197 INSULET CORP PODD 0001665678 Alpuche Charles C/O INSULET CORPORATION 100 NAGOG PARK ACTON MA 01720 1 Advisor Common Stock 2023-03-13 4 M 0 23401 31.21 A 68985 D Common Stock 2023-03-13 4 S 0 23401 305.15 D 45584 D Employee Stock Option (Right to Buy) 31.21 2023-03-13 4 M 0 23401 0 D 2026-02-03 Common Stock 23401 12347 D The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $302.98 to $307.17. Specifically: 8,975 shares were sold in the range of $302.98 to $303.98, with a weighted average share price of $303.60; 1,100 shares were sold in the range of $304.01 to $304.29, with a weighted average share price of $304.08; 7,524 shares were sold in the range of $305.35 to $306.35, with a weighted average share price of $305.94; Footnote continued: and 5802 shares were sold in the range of $306.41 to $307.17, with a weighted average share price of $306.74. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price. This option is subject to a four-year vesting period, with 25% of the total award vesting one year after the grant date and the remainder vesting in equal quarterly installments each quarter thereafter for 12 quarters, subject to continued employment. /s/ Patricia K. Dolan, attorney-in-fact 2023-03-14